• Crizocent 250 Mg (Crizotinib) Quick View
  • Lorbrexen 100 Mg (Lorlatinib) Quick View
    • Lorbrexen 100 Mg (Lorlatinib) Quick View
    • Lorbrexen 100 Mg (Lorlatinib)

    • Lorbrexen 100 mg (Lorlatinib), generic Lorbrena is a prescription medicine used to treat metastatic non-small cell lung cancer in patients who have a certain type of abnormal anaplastic lymphoma kinase (ALK) gene. It is used in patients who have already received alectinib, ceritinib, or both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the…
    • Read more
  • Osicent 80mg (Osimertinib) Quick View
    • Osicent 80mg (Osimertinib) Quick View
    • Osicent 80mg (Osimertinib)

    • Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type. In cultured cells and animal tumor implantation models, osimertinib exhibited anti-tumor activity against non-small cell lung cancer (NSCLC) lines harboring EGFR-mutations (T790M/L858R, L858R, T790M/exon 19 deletion, and…
    • Read more
  • Osimert 80mg (Osimertinib) Quick View
  • Sotoxen 120mg (Sotorasib) Quick View
    • Sotoxen 120mg (Sotorasib) Quick View
    • Sotoxen 120mg (Sotorasib)

    • Sotoxen 120 Mg (Sotorasib) is used to treat a certain type of lung cancer (non-small cell lung cancer; NSCLC) that has spread to other parts of the body or cannot be removed by surgery in adults who have received at least one other treatment. Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action…
    • Read more
  • Tagrix- 80mg (Osimertinib) Quick View
    • Tagrix- 80mg (Osimertinib) Quick View
    • Tagrix- 80mg (Osimertinib)

    • Tagrix is the 1st global generic of osimertinib. This drug is a third generation EGFR inhibitor. Osimertinib (Tagrix) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M  mutation.
    • Read more